Agios Q2 2026 mitapivat revenue $44.7M; net loss $100.7M; FDA Priority Review for sickle cell sNDA

AGIOS PHARMACEUTICALS, INC.

Mitapivat worldwide net revenue $44.7M (Q2 2026) vs $12.5M (Q2 2025); U.S. $40.9M, ex-U.S. $3.8M.
FDA granted Priority Review for mitapivat sNDA in sickle cell disease; PDUFA date Nov 1, 2026.
Licensed cevidoplenib from Oscotec for ITP; up to $1B peak U.S. sales potential; $25M up-front payment.
Discontinued tebapivat in LR-MDS and sickle cell disease; advancing AG-236 to Phase 2/3 for polycythemia vera.
Cash, equivalents, and marketable securities $964.8M as of June 30, 2026; net loss $100.7M vs $112.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.